BIDMC/ DF-Harvard CC
Oncology
Dr. Steven E. Come, MD
|
|
Give Review
Dr. Steven E. Come is an expert in the field of Oncology. He went to medical school at Harvard Medical School. Harvard Medical School is a top medical college. Harvard Medical School is ranked 1 in research and 12 in primary care medicine He received awards:"America's Top Doctors", "Boston Magazine", "America's Top Doctors for Cancer", "Meaningful Use Stage 1 Certification", "Boston Herald", "Redbook Magazine: Top Breast Cancer Doctors" and "Super Doctor". Dr. Steven E. Come is also published. He has 93 publications published. The lastest publication: "Why and how to combine chemotherapy and radiation therapy in breast cancer patients.' Dr. Steven E. Come accepts Medicare.
Publications
- Local Therapy Decision-Making and Contralateral Prophylactic Mastectomy in Young Women with Early-Stage Breast Cancer.
- Partner support and anxiety in young women with breast Cancer.
- Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2-Negative (or unknown) Advanced Breast Cancer: American Society of Clinical On...
- Drug withdrawal in women with progressive metastatic breast Cancer while on aromatase inhibitor therapy.
- Treatment-related amenorrhea and sexual functioning in young breast Cancer survivors.
- Prospective Study of Fertility Concerns and Preservation Strategies in Young Women With Breast Cancer.
- A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast Cancer.
- Breast Cancer presentation and diagnostic delays in young women.
- A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast Cancer brain metastases.
- Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with...
- Body image in recently diagnosed young women with early breast Cancer.
- A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast Cancer.
- Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast Cancer.
- Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast Cancer.
- Update: a 62-year-old woman with a new diagnosis of breast Cancer.
- Endocrine and targeted manipulation of breast Cancer: summary statement for the Sixth Cambridge Conference.
- Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast Cancer: unexpected incidence of hypersensitivity reactions.
- Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast Cancer.
- Inadvertent use of aromatase inhibitors in patients with breast Cancer with residual ovarian function: cases and lessons.
- A 62-year-old woman with a new diagnosis of breast Cancer.
- Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: conference summary statement.
- Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast Cancer chemotherapy.
- Fulvestrant versus anastrozole for the treatment of advanced Breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials.
- Role of fulvestrant in sequential hormonal therapy for advanced, hormone receptor-positive breast Cancer in postmenopausal women.
- Sequencing of chemotherapy and radiation therapy in early-stage breast Cancer: updated results of a prospective randomized trial.
- Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement.
- A prospective study of concurrent cyclophosphamide/methotrexate/5-fluorouracil and reduced-dose radiotherapy in patients with early-stage Breast carcinoma.
- Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement.
- Fulvestrant versus anastrozole for the treatment of advanced Breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
- Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement.
- Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast Cancer.
- Staging in non-Hodgkin''s Lymphoma: approach, results and relationship to histopathology.
- Issues of controversy in radiation therapy and combined modality approaches to Hodgkin''s Disease.
- Adriamycin therapy for advanced insulinoma.
- Integration of conservative surgery, radiotherapy, and chemotherapy for the treatment of early-stage, node-positive breast Cancer: sequencing, timing, and outcome.
- Cisplatin, continuous-infusion 5-fluorouracil, and intermediate-dose methotrexate in the treatment of unresectable non-small cell Carcinoma of the lung.
- Elevated creatine kinase and malignancy.
- Breast Cancer chemotherapy: perioperative considerations in breast reconstruction.
- Stage III Hodgkin's Disease: improved survival with combined modality therapy as compared with radiation therapy alone.
- Reversible right ventricular outflow Tract compression by immunoblastic sarcoma.
- Therapeutic embolization of the gastroduodenal artery in hepatic artery infusion chemotherapy.
- Biochemical pharmacology in medical oncology.
- Chemotherapy in the treatment of Hodgkin's Disease.
- Surface remodelling of reticulocytes produced in response to erythroid stress.
- Surface remodeling vs. whole-cell hemolysis of reticulocytes produced with erythroid stimulation or iron deficiency Anemia.
- cis-Diamminedichloroplatinum(II) therapy for advanced ovarian Cancer.
- Non-Hodgkin's Lymphomas in leukemic phase: clinicopathologic correlations.
- Echocardiographic manifestations of carcinoid heart Disease.
- Pulmonary uptake of technetium 99m macroaggregated albumin: a predictor of gastrointestinal toxicity during hepatic artery perfusion.
- Radionuclide angiography to predict patient response to hepatic artery chemotherapy.
- Adjuvant chemotherapy for breast Cancer.
- Paradoxical emetic response to antiemetic treatment in Cancer patients.
- Use of pulmonary capillary wedge aspirates for the antemortem diagnosis of pulmonary microvascular tumor.
- Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's Disease and non-Hodgkin's lymphoma: a dose-finding study.
- Sequencing of irradiation and chemotherapy for early-stage breast Cancer.
- Proceedings of the First International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: summary consensus statement.
- Concurrent CMF and radiation therapy for early stage breast Cancer: results of a pilot study.
- Treatment-related toxicity from a randomized trial of the sequencing of doxorubicin and radiation therapy in patients treated for early stage breast Cancer.
- Long-term results of post-operative radiation therapy following mastectomy with or without chemotherapy in stage I-III breast Cancer.
- The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast Cancer.
- Endocrine treatment options for advanced breast Cancer--the role of fulvestrant.
- Troponin I and C-reactive protein are commonly detected in patients with breast Cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib.
- Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast Cancer is not feasi...
- Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction.
- Review of gene-expression profiling and its clinical use in breast Cancer.
- Pharmacokinetic profile of intramuscular fulvestrant in advanced breast Cancer.
- Mantle irradiation alone for selected patients with laparotomy-staged IA to IIA Hodgkin's Disease: preliminary results of a prospective trial.
- Conservative surgery and radiotherapy for early breast Cancer.
- Invasive pulmonary aspergillosis in an apparently nonimmunocompromised host.
- The effect of adjuvant chemotherapy on the cosmetic results after primary radiation treatment for early stage breast Cancer.
- Improved survival following combined radiation therapy and chemotherapy for unfavorable prognosis stage I-II non-Hodgkin's Lymphomas.
- Current status of conservative surgery and radiotherapy as primary local treatment for early carcinoma of the Breast.
- Sequential multi-agent chemotherapy and whole abdominal irradiation for stage III ovarian Carcinoma.
- Primary radiation therapy for locally advanced breast Cancer.
- New agents and new medical treatments for advanced breast Cancer.
- Conservative surgery and radiation therapy for early breast Cancer: results, controversies, and unsolved problems.
- High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast Cancer.
- Prognosis following local or regional recurrence after conservative surgery and radiotherapy for early stage Breast carcinoma.
- Premenopausal breast Cancer patients treated with conservative surgery, radiotherapy and adjuvant chemotherapy have a low risk of local failure.
- Cosmetic results after surgery, chemotherapy, and radiation therapy for early breast Cancer.
- Hepatic arterial BCNU: a pilot clinical-pharmacologic study in patients with Liver tumors.
- A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2''-deoxyuridine and 5-fluorouracil.
- Case mix and charges for inpatient and outpatient chemotherapy.
- Why and how to combine chemotherapy and radiation therapy in breast Cancer patients.
- Correlation of tumor size and axillary lymph node involvement with prognosis in patients with T1 Breast carcinoma.
- Skin recurrences after breast-conserving therapy for early-stage breast Cancer.
- Treatment outcome after tangential radiation therapy without axillary dissection in patients with early-stage breast Cancer and clinically negative axillary nodes.
- Long-term survival in Hodgkin's Disease relative impact of mortality, second tumors, infection, and cardiovascular Disease.
- Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's Disease: long-term analysis of risk factors and outcome.
- Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast Cancer.
- Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast Cancer progressin...
- BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer.
Schools
Harvard Medical School
Beth Israel Hospital
National Cancer Institute
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anemia
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- Boston Magazine
- America's Top Doctors for Cancer
- Meaningful Use Stage 1 Certification
- Boston Herald
- Redbook Magazine: Top Breast Cancer Doctors
- Super Doctor
Education
-
Beth Israel Deaconess Medical Center -
Harvard Medical School
Hospital
-
Beth Israel Deaconess Medical Center
Drug Facts
| NPI NUMBER | 1619940137 | |
| NPPES Provider LastName | COME | |
| NPPES Provider FirstName | STEVEN | |
| NPPES Provider ZIPCode | 022155400 | |
| NPPES Provider State | MA | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 211.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1619940137 |
| Last Name Of The Provider | COME |
| First Name Of The Provider | STEVEN |
| View All |
Similar Doctors
|
|
Dr. Meghan J. Campo, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sarah Schellhorn, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Gabriel A. Brooks, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ephraim P. Hochberg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark S. Huberman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Craig A. Bunnell, MD
This Doctor is OpenDoctor Recommended.
|